for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

However, they also respond more quickly to treatment, according to Cleveland Clinic. The most common type is diffuse large ...

Full House; actor Dave Coulier said he was diagnosed with stage 3 non-Hodgkin lymphoma in October and he has began ...

Researchers sought to determine whether liso-cel could be safely administered as an outpatient therapy in relapsed/refractory LBCL.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the ...

Dave Coulier has been diagnosed with Stage 3 Non-Hodgkin lymphoma, after noticing a golf ball-sized swelling in his groin.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Two oral presentations on the ELM-1 and pivotal ELM-2 trials will feature new analyses in settings with significant unmet needs: one in patients with diffuse large B-cell lymphoma who progressed after ...

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase ...

Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...